Related Experiment Video
Updated: Mar 16, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
10.5K
Pharmacogenetics in Oral Antithrombotic Therapy
Cheryl L Maier1, Alexander Duncan1, Charles E Hill1
1Department of Pathology and Laboratory Medicine, Emory University Hospital, Emory University School of Medicine, 1364 Clifton Road Northeast, Atlanta, GA 30322, USA.
Clinics in Laboratory Medicine
|August 13, 2016
Summary
Pharmacogenetics can personalize antithrombotic drug therapy due to significant patient variability. Genetic testing is recommended for warfarin and clopidogrel, with ongoing research for newer agents.
Area of Science:
- Pharmacology
- Genetics
- Internal Medicine
Background:
- Antithrombotic drug therapy shows significant patient-to-patient variability, impacting safety and efficacy.
- Pharmacogenetics enables personalized medicine by tailoring treatments to individual genetic profiles.
- Current pharmacogenetic applications are established for warfarin and clopidogrel, guiding their use and dosing.
Purpose of the Study:
- To provide an overview of the current status of pharmacogenetics in oral antithrombotic therapy.
- To highlight the role of genetic variations in drug response.
- To discuss the clinical relevance of pharmacogenetic testing for antithrombotic agents.
Main Methods:
- Literature review of pharmacogenetic studies on oral antithrombotic drugs.
- Analysis of existing recommendations for pharmacogenetic testing.
- Evaluation of identified genetic polymorphisms affecting drug metabolism and activity.
Main Results:
- Pharmacogenetic testing is recommended for warfarin and clopidogrel to optimize therapy.
- Limited studies exist on polymorphisms affecting newer oral antithrombotic drugs.
- Clear evidence of clinical relevance for polymorphisms in newer agents is lacking.
Conclusions:
- Pharmacogenetics holds significant potential for optimizing oral antithrombotic therapy.
- Further research is needed to establish the clinical utility of pharmacogenetic testing for newer antithrombotic drugs.
- Personalized antithrombotic treatment based on genotype is an evolving field.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
94
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
94
01:27Pharmacogenetics of Drug Metabolism: Overview
90
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
90
01:29Pharmacogenomics: Identification of New Drug Targets
73
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
73
01:29Pharmacogenetics and Pharmacogenomics: Overview
127
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
127
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63